Cervical Cancer Diagnostics Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Cervical Cancer Diagnostics Market is segmented By Test Type (Pap Smear Test, HPV Test, Colposcopy test, Imaging Tests, Cervical Biopsies, Biomarker testing), By Age Group (20-30 years and Above 30 years), By Cancer Type (Squamous cell carcinoma, Adenocarcinoma, Small Cell Neuroendocrine Carcinoma), By Stage (Stage I, Stage II, Stage III, Stage IV), By End User (Hospitals and Clinics, Cancer Diagnostic Centers, Cancer Research Institutes), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Report Overview

Global Cervical Cancer Diagnostics Market reached US$ YY Million in 2022 and is expected to reach US$ YY  Million by 2030 growing with a high CAGR during the forecast period 2023-2030.

Cervical cancers are caused by the virus HPV, a sexually transmitted infection. HPV spreads through sexual contact (anal, oral, or vaginal) and can lead to cancer. Cervical cancer can be detected through various screening tests. The most common screening test for cervical cancer or precancerous cells (dysplasia) is the Pap test. 

About 80% to 90% of cervical cancers are squamous cell carcinomas, while 10% to 20% are adenocarcinomas. About 14,000 people in the United States are diagnosed with cervical cancer yearly. People between the ages of 35 and 44 are most frequently diagnosed with cervical cancer. The average age at diagnosis is 50. Around 4,000 people die of cervical cancer per year. This rate is on the decline due to screenings and the HPV vaccine.

Market Scope

For More Insights about the Market Request Free Sample

Market Dynamics

Increasing product approvals

Early cervical cancer diagnosis decreases the burden of disease treatment as the cancer undergoes staging, which makes it harder to diagnose and treat the disease. The leading cause of cervical cancer is the human papillomavirus. Hence, an HPV test is done to diagnose cervical cancer. The development of new HPV tests can increase the chance of accuracy compared to obsolete tests like pap smears. Increasing approvals makes it easier for the availability of the test kit in the market. 

For instance, in June 2022, Karkinos Healthcare, an oncology-concentrated health-tech platform, introduced CerviRaksha. This foremost clinically validated HPV test is prequalified by the WHO and authorized by the FDA in collaboration with the Karkinos network clinic physicians and nursemaids.

In February 2023, Becton, Dickinson, and Company received approval from the U.S. Food and Drug Administration (FDA) for its BD Onclarity HPV Assay. The BD Onclarity HPV Assay detects human papillomavirus (HPV).

The increasing adoption of Artificial Intelligence and deep learning in cancer screening modalities, technological advancements in diagnostic procedures, and rising awareness about cervical cancer are a few factors that drive the market in the forthcoming period.

False positive test results

False-positive tests are defined as positive screening tests that are not eventually confirmed with high-grade cervical intraepithelial neoplasia (CIN). The growing false positive results are hampering the global cervical cancer diagnostics market growth in the forecast period. For instance, in a study for annual, 3-year, and 5-year triage testing (either LBC with HPV reflex or vice versa), the lifetime chance of a false positive is 35.1%, 13.4%, and 8.3% respectively.

Segment Analysis

The global cervical cancer diagnostics is segmented based on test type, cancer type, age group,  stage, end user, and region.

The HPV tests segment accounted for approximately xx% of the market share 

An increase in the advancements in screening procedures made testing easy for diagnosing cervical cancer. Several Key companies such as F. Hoffmann-La Roche AG, SANSURE BIOTECH INC., and LifeCell International are developing HPV kits, making it easy for in-home screening of HPV among individuals. 

In January 2022, SANSURE BIOTECH INC., an in-vitro diagnostic developments supplier, declared that its ‘HPV DNA Diagnostic Kit (HPV 13+2)’ was authorized by the China National Medical Products Administration (NMPA).

Additionally, in June 2023, LifeCell International launched a self-sampling test kit to help detect cervical cancer-causing viruses. Hence, the product launch increase will drive the market in the forthcoming period.

Geographical Analysis

North America accounted for approximately XX% of the market share in 2022

North America is estimated to dominate the global cervical cancer diagnostics market. For instance, January has been established as "Cervical Health Awareness Month" by the United States Congress. 

The National Cervical Cancer Coalition (NCCC) and its multiple local chapters all over the nation increase awareness regarding cervical cancer, HPV disease, and the significance of earlier diagnosis during January. It is performed to increase community awareness regarding cervical cancer diagnosis and its complications after staging. 

In May 2022, the U.S. Department of Health and Human Services (HHS), declared the availability of US$ 5 million for community health centers, funded by HHS’s Health Resources and Services Administration, to increase equitable access to life-saving cervical cancer screenings which makes the screening procedures cost-effective that leads to early detection of cervical cancer in US patients. Hence, the above factors are expected to hold the largest market share in the North American region.

COVID-19 Impact Analysis

The market saw a rise in molecular diagnostic methods, such as HPV DNA testing, and a shift towards personalized medicine. HPV vaccination programs also played a role in preventing cervical cancer, but regular screening was still crucial for early detection and treatment. Increased demand for diagnosing and therapeutic devices has risen dramatically in hospitals. For instance, the need for ventilators, respirators, and in vitro diagnostic (IVD) tests has drastically increased in hospitals across the countries in the region.

Competitive Landscape

The major global players in the cervical cancer diagnostics market include F. Hoffmann-La Roche AG, QIAGEN, DaAnGene, Molbio Diagnostics, Cepheid, Norgen Biotek Corp., Atila Diagnostics, Abbott Laboratories, Life Cell International, and Sansure Biotech among others.

Key Developments

• In June 2023 by LabMedica, low-cost DNA tests for HPV infections could improve access to cervical cancer screening. Rice University bioengineers have developed a low-cost, point-of-care DNA test for HPV infections.
• In March 2023, Roche Products (India) Pvt. Ltd., signed a Memorandum of Understanding (MoU) with the Cancer Awareness Prevention and Early Detection Trust (CAPED), a non-profit organization dedicated to promoting cancer awareness, prevention, and early detection of cervical, ovarian cancer and other types of cancers. 

Why Purchase the Report?

• To visualize the global cervical cancer diagnostics segmentation based on test type, cancer type, age group, stage, end user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of cervical cancer diagnostics market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global cervical cancer diagnostics market report would provide approximately 77 tables, 82 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies